← Back to Search

Immunomodulator

Single Arm for Cutaneous T-Cell Lymphoma

Phase < 1
Waitlist Available
Led By Ali Dana, MD
Research Sponsored by James J. Peters Veterans Affairs Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial is studying how well using a combination of antibiotics and imiquimod works in treating patients with cutaneous T-cell lymphoma.

Eligible Conditions
  • Cutaneous T-Cell Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pilot assessment of response.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment2 Interventions
Doxycycline 100 mg PO BID x 14 days, then Imiquimod up to 2 packs 3/ week x 28 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Imiquimod
FDA approved
Doxycycline
FDA approved

Find a Location

Who is running the clinical trial?

James J. Peters Veterans Affairs Medical CenterLead Sponsor
57 Previous Clinical Trials
2,892 Total Patients Enrolled
Ali Dana, MDPrincipal InvestigatorJames J. Peters VAMC

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~1 spots leftby Apr 2025